A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

← catalyst calendar

NCT07318805 · readout in 969 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

260estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-12-23

actual

When the study began enrolling

Primary completion

2029-04-14

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2030-04-14

estimated

The whole study's end, after follow-up

First posted

2026-01-06

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-22

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Advanced Breast Cancer
Metastatic Breast Cancer (HR+/ HER2-)
Colorectal Cancer
Metastatic Colorectal Adenocarcinoma
Triple Negative Breast Cancer

Interventions

Drug: PF-08032562
Drug: Fulvestrant — also filed as Faslodex
Drug: Cetuximab — also filed as Erbitux, Enlituo
Drug: Fluorouracil — also filed as 5-FU, 5-Fluorouracil
Drug: Oxaliplatin — also filed as Eloxatin
Drug: Leucovorin — also filed as Folinic Acid, Wellcovorin, Calcium Folinate
Drug: Bevacizumab — also filed as Zirabev, Avastin

Primary outcomes

what the primary-completion date above is the date OF

Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT)

measured Baseline up to 28 days

Part 1 (Dose Escalation): Number of participants with laboratory abnormalities

measured From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

Part 1 (Dose Escalation): Incidence of Adverse Events (AEs)

measured From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

Part 2 (Dose Expansion): Objective Response Rate (ORR)

measured Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed